Medication Review in Women With Depression and Anxiety
Assessing the Impact of Medication Management Review Service for Females Diagnosed With Depression and Anxiety
Assessing the Impact of Medication Management Review Service for Females Diagnosed With Depression and Anxiety
Sponsor study identifier
interventional
73
0 countries
N/A
Study Start
August 1, 2016
Actual (reported)Primary Completion
January 1, 2017
Actual (reported)Study Completion
January 10, 2017
Actual (reported)This study sought to assess the impact of the MMR service on identifying and resolving TRPs, improving adherence, depression and anxiety scores in females diagnosed with depression and anxiety in Jordan
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 10, 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1, 2016
Actual (reported)January 1, 2017
Actual (reported)January 10, 2017
Actual (reported)September 2, 2019
Actual (reported)September 9, 2019
Actual (reported)Evaluate the effect of the medication management review service delivered to females living in Jordan and diagnosed with depression and anxiety
the medication management review service will be measured by the reduction of treatment related number after providing the service
6 months
Patient's satisfaction with the medication management review service
6 months
All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist. A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied. If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist.
Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations. After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist
The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
73 participants (actual enrollment reported by the registry).
First Submitted
Contact the study team to confirm eligibility.
September 2, 2019
First Posted
September 9, 2019
Study Start
August 1, 2016
Actual (reported)Primary Completion
January 1, 2017
Actual (reported)Study Completion
January 10, 2017
Actual (reported)Last Updated
September 9, 2019
Record last verified: 2019-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: